MLYS vs. TARS, JANX, AGIO, NAMS, IDYA, SDGR, TVTX, BLTE, VERA, and IOVA
Should you be buying Mineralys Therapeutics stock or one of its competitors? The main competitors of Mineralys Therapeutics include Tarsus Pharmaceuticals (TARS), Janux Therapeutics (JANX), Agios Pharmaceuticals (AGIO), NewAmsterdam Pharma (NAMS), IDEAYA Biosciences (IDYA), Schrödinger (SDGR), Travere Therapeutics (TVTX), Belite Bio (BLTE), Vera Therapeutics (VERA), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.
Mineralys Therapeutics vs.
Tarsus Pharmaceuticals (NASDAQ:TARS) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, community ranking, risk, earnings, valuation and institutional ownership.
Tarsus Pharmaceuticals has higher revenue and earnings than Mineralys Therapeutics. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Mineralys Therapeutics, indicating that it is currently the more affordable of the two stocks.
90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are held by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are held by insiders. Comparatively, 33.2% of Mineralys Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Tarsus Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.
Mineralys Therapeutics has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -103.64%. Tarsus Pharmaceuticals' return on equity of -55.86% beat Mineralys Therapeutics' return on equity.
In the previous week, Tarsus Pharmaceuticals had 4 more articles in the media than Mineralys Therapeutics. MarketBeat recorded 5 mentions for Tarsus Pharmaceuticals and 1 mentions for Mineralys Therapeutics. Tarsus Pharmaceuticals' average media sentiment score of 0.87 beat Mineralys Therapeutics' score of 0.25 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.
Tarsus Pharmaceuticals received 32 more outperform votes than Mineralys Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Mineralys Therapeutics an outperform vote while only 66.67% of users gave Tarsus Pharmaceuticals an outperform vote.
Tarsus Pharmaceuticals presently has a consensus target price of $56.00, indicating a potential upside of 17.06%. Mineralys Therapeutics has a consensus target price of $27.00, indicating a potential upside of 182.43%. Given Mineralys Therapeutics' higher probable upside, analysts clearly believe Mineralys Therapeutics is more favorable than Tarsus Pharmaceuticals.
Summary
Tarsus Pharmaceuticals beats Mineralys Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Mineralys Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLYS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mineralys Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLYS) was last updated on 2/21/2025 by MarketBeat.com Staff
